Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04477785 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Study acronym: PPMI
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 80 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 50 sitesv80
  2. Site contacts updated at 2 of 50 sitesv79
  3. Site contacts updated at 1 of 50 sitesv78
  4. Site details revised at 7 of 50 sitesv77
  5. Site contacts updated at 1 of 50 sitesv76
Show 45 earlier versionsHide 45 earlier versions
  1. Site contacts updated at 1 of 50 sitesv75
  2. Study sites: 51 to 50v74
  3. Site contacts updated at 1 of 51 sitesv73
  4. Study sites revised (51)v72
  5. Site contacts updated at 1 of 51 sitesv71
  6. Site contacts updated at 8 of 51 sitesv70
  7. Site contacts updated at 1 of 51 sitesv69
  8. Eligibility criteria revised
    • Site details revised at 1 of 51 sites
    v68
  9. Primary endpoints revised (5)v67 Show 4 more changesShow less
    • Study sites: 50 to 51
    • Eligibility criteria expanded, about 841 words
    • Study description shortened, about 6 words
    • Study title revised
  10. Site contacts updated at 1 of 50 sitesv66
  11. Site contacts updated at 1 of 50 sitesv65
  12. Site contacts updated at 1 of 50 sitesv64
  13. Study sites: 49 to 50v63
  14. Study sites: 50 to 49v62
  15. Site contacts updated at 1 of 50 sitesv61
  16. Study sites: 51 to 50v60
  17. Study sites: 50 to 51v59
  18. Site details revised at 3 of 50 sitesv58
  19. Site details revised at 1 of 50 sitesv57
  20. Site details revised at 1 of 50 sitesv56
  21. Site details revised at 1 of 50 sitesv55
  22. Study sites: 49 to 50v54
  23. Site details revised at 2 of 49 sitesv53
  24. Site details revised at 1 of 49 sitesv52
  25. Site details revised at 1 of 49 sitesv51
  26. Site contacts updated at 31 of 49 sitesv50
  27. Site details revised at 2 of 49 sitesv49
  28. Site contacts updated at 1 of 49 sitesv48
  29. Site details revised at 4 of 49 sitesv47
  30. Site details revised at 1 of 49 sitesv46
  31. Site details revised at 1 of 49 sitesv45
  32. Site contacts updated at 1 of 49 sitesv44
  33. Site contacts updated at 1 of 49 sitesv43
  34. Site details revised at 2 of 49 sitesv42
  35. Site contacts updated at 1 of 49 sitesv41
  36. Site details revised at 1 of 49 sitesv40
  37. Site contacts updated at 1 of 49 sitesv39
  38. Site details revised at 2 of 49 sitesv38
  39. Site contacts updated at 1 of 49 sitesv37
  40. Site contacts updated at 1 of 49 sitesv36
  41. Site contacts updated at 1 of 49 sitesv35
  42. Site details revised at 1 of 49 sitesv34
  43. Site details revised at 2 of 49 sitesv33
  44. Site details revised at 1 of 49 sitesv32
  45. Site details revised at 2 of 49 sitesv31
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Trial Details
NCT Number NCT04477785
Lead Sponsor Michael J. Fox Foundation for Parkinson's Research
Collaborators: Institute for Neurodegenerative Disorders
Conditions
(from sponsor)		 Parkinson Disease
Related terms Anosmia, Neurodegenerative Diseases, Parkinson Disease
Enrollment 4,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov